Breakdown in Maternal Protection: Drugs by Jean Ginsburg DM (Royal Free Hospital School ofMedicine, London)
Over 100 years ago, Claude Bernard (1859) described the placenta as 'un veritable organe hepatique'. And whilst there are a number of differences between the placenta and liver from a strictly biochemical point of view (Ginsburg & Jeacock 1968) , the analogy holds for many aspects of its function.
Nevertheless, the influence on feetal activity of drugs given to pregnant women is conventionally related to the amount of the drug in question which effectively reaches the foetus, and the most important consideration in assessing feetal effects after maternal drug administration has been the extent of drug transfer across the placenta. The use of the term 'placental barrier' typifies our concept in this regard, the placenta being considered essentially as a protective layer providing a physical barrier to the passage of noxious substances from mother to feetus. Admittedly, in a very general sense, small molecules cross the placenta faster than large ones and foetal involvement in systemic maternal infection is fortunately not common, especially in the later stages of gestation. But the rate of passage across the placenta of most substances is not a function of molecular size alone. Gamma globulins, for example, are transferred from mother to foetus in greater amounts than the small albumin molecules and many low molecular weight drugs such as d-tubocurarine cannot be detected in foetal blood unless excessively high doses are given to the mother. The placenta is not a semipermeable membrane across which substances pass by simple diffusion from regions of high to lower concentrations. The fact that the concentration of amino acids and vitamins and other compounds in the umbilical vein is greater than that in maternal plasma is but one example of the selective and active nature of placental transfer.
For obvious reasons, there are few quantitative data on the kinetics of drug transfer across the human placenta during normal pregnancy. Theoretically drugs may cross the placenta by any of the mechanisms thought responsible for the transfer of essential nutrients and metabolites to the foetus (Ginsburg & Jeacock 1964a) but the available studies indicate that the rate of placental drug transfer depends both on the lipid solubility of the drug in question and on its degree of ionization (Moya & Thorndike 1962 , Villee 1967 . Non-ionized drugs of high lipid solubility, such as thiopentone or antipyrin, cross very much more rapidly than those which are highly dissociated or which have a low lipid solubility. The mechanism of transfer of drugs across the placental barrier apparently resembles that across the blood-brain barrier and hence sedatives, anesthetics, and central nervous system depressants will readily and rapidly reach the foetus.
But in fact any substance given to the mother, if present in sufficient quantity in the maternal circulation, can and will reach the feetus. Whether or not significant amounts reach foetal tissues in this way depends not only on the lipid solubility of the drug and on its state of dissociation, but also on the extent to which it is metabolized, both by maternal tissues and by the placenta itself. And, similarly, the effect on the foetus is not solely determined by the extent of placental transfer but relates also to the influence exerted by a particular drug on maternal or placental function.
To consider drugs as causing a breakdown in maternal protection is thus an oversimplification. Assessment of potential drug influences on the developing foetus requires consideration of:
(1) Drug effects on maternal metabolism and the extent to which maternal tissues and the placenta degrade the compound in question; and it must not be forgotten that the rate of drug metabolism may alter in pregnancy, possibly in consequence of the altered hormonal environment (Crawford & Rudofsky 1966) . (2) The extent of its transfer across the placenta. (3) The effect of the drug on metabolic processes in the placenta.
It is this last aspect of drug action in pregnancy, which indeed may have the most important consequences for feetal development, that I propose to consider in more detail.
The classic studies of Villee and his collaborators have shown that even at term, when in consequence of histological changes the placenta has been considered a senescent and degenerating tissue, its cells are still extremely active metabolically and carry out a wide spectrum of catabolic and synthetic processes (Villee 1962 ). The placenta not only transports metabolites and essential nutrients to the feetus but utilizes some of them for its own metabolic requirements and for the synthesis of basic constituents of foetal tissues. In discussing certain aspects of placental metabolism I shall describe some studies which have been carried out in our laboratory by a number of workers both individually and together. It has fallen upon me to present some aspects of this work and I am particularly grateful to my colleagues for providing me with some of their unpublished data for this purpose. The studies I shall present were undertaken, first, to investigate the pathways utilized and inter-nucleic acid and ribose turnover and protein synthesis were correspondingly high, whereas in the term placenta, where there was no measurable utilization of the pentose route, nucleic acid and ribose turnover and protein synthesis were much less , Beaconsfield et al. 1965 .
Pharmacological agents which influenced pentose shunt activity also induced corresponding changes in ribose formation, nucleic acid turnover and protein synthesis. Thus, liver alcohol de--J I I hydrogenase (L-ADH) depressed glucose metab- mediates produced during carbohydrate, protein and fat metabolism in the normal human placenta, and, secondly, to determine whether the pattern of placental metabolism altered quantitatively or qualitatively during gestation, under the influence of hormones or drugs and in abnormal pregnancy.
Theinitial studieswereconcerned with the pathways of glucose metabolism in the normal human placenta. The relative utilization of the glycolytic and direct oxidative pathways for glucose catabolism were assessed in relation to the amount of labelled carbon dioxide produced after parallel incubation of fresh slices of placental tissue with differentially labelled glucose. The relative utilization of the pentose phosphate pathway for glucose metabolism in human placente was found to vary with the stage of gestation. In early placentm, i.e. between 6 and 20 weeks gestation, pentose phosphate pathway activity was much greater than at term (Fig 1) (Ginsburg & Jeacock 1964b . The finding of an elevated hexose monophosphate pathway activity in the early proliferating placenta parallels the raised pentose pathway demonstrated in other tissues during periods of active growth, as in the lactating mammary gland (Glock et al. 1956 ), healing wounds (Beaconsfield 1963) and rapidly growing carcinomata (Beaconsfield & Rainsbury 1964) . In placente from abortus specimens, pentose pathway activity was barely measurable (Beaconsfield & Morris 1967) , though whether this is a consequence of feetal death or bears a causal relation is not known.
A parallelism was also demonstrated between the extent of glucose metabolism by the pentose route in the human placenta and the corresponding rates of nucleic acid and ribose turnover and protein synthesis. Thus, when pentose pathway activity was elevated, as in the early placenta, rate of glycolytic activity is increased by exogenous adrenaline, as indicated by greater placental lactate production and glycogen breakdown, the magnitude of the effects being related to the amount of hormone added; in addition placental glucose uptake was increased in these circumstances (Fig 4) (Ginsburg 1966 , Ginsburg & Jeacock 1968 ). Placental lactate output was also increased in anoxic conditions (Fig 5) (Ginsburg 1966 , Ginsburg & Jeacock 1968 ). Other substances, e.g. oxytocin and urea, were also found to influence the pattern of placental carbohydrate metabolism (Ginsburg & Jeacock 1967a, and 1968 unpublished) . These studies have shown that synthetic and catabolic aspects of placental metabolic function can be modified by the action of various agents, irrespective of the extent of transfer of these compounds across the placental barrier. Indeed, rapid placental transfer might minimize drug influence on placental metabolism, and conversely, drugs which do not reach the foetus in significant amounts may exert profound effects on the pattern of placental metabolism.
Since the foetus is entirely dependent on its placenta, changes in the metabolic activity of this organ, whether physiologically or pharmacologically induced, must have repercussions on foetal function. The possibility that teratogenic agents may exert their effect, at least in part, by influencing placental metabolism certainly requires investigation. It is relevant that some substances which do not cross the placenta, such as trypan blue, nevertheless produce foetal mal- other tissues is also being investigated. Oxytocin, which increases carbon dioxide production from glucose labelled in the first carbon atom in adipose tissue (Mirsky & Perisutti 1961) , has a similar effect in the early human placenta (Ginsburg & Jeacock 1968, unpublished) .
Other aspects of placental carbohydrate metabolism have also been studied, for example the rate of glycolysis as indicated by lactate production. The normal human placenta has a relatively high rate of aerobic glycolysis, and the basal level of placental lactate production is somewhat greater in the early weeks of gestation than at term (Ginsburg & formations (Tuchmann-Duplessis 1965) . The full assessment of foetal consequences of any compound given to pregnant women thus requires study of the effect of such compounds on the pattern of placental metabolism. Such studies must be carried out in human tissue. Rodents will not suffice for this purpose, for though in the majority of tissues the pattern of metabolism in the rat has been held to typify, at least qualitatively, that occurring in the corresponding human tissue, the differences in metabolic processes demonstrated between rat and human placentw (Ginsburg & Jeacock 1967b) limit the use of the rodent in this respect. Our own metabolic studies have shown that basal lactate production, for example, is very much higher in the rat placenta than in human tissue and that it is unaffected by the addition of adrenaline or by anoxia ( Fig 6) (Ginsburg & Jeacock 1967b) .
Studies of drug influences on placental metabolism must, therefore, be made in human tissue and in physiological conditions, if reasonable predictions are to be made of potential foetal effects of drugs taken by pregnant women. For this purpose perfusion techniques such as those developed by Panigel (1962) should be used in addition to classical incubation procedures. The active metabolic potential of the human placenta at all stages of gestation thus reflects not only its ability to limit the amount of a particular drug which effectively reaches the feetus but also the reverse, namely that drugs can affect the pattern of placental metabolism and that this will influence foetal activity irrespective and independently of other maternal or foetal drug effects.
DISCUSSION
The Chairman asked Dr Ginsburg whether in the reactions studied she had been able to separate the different tissue layers of the placenta and whether the responses varied between these layers. Dr Ginsburg replied that studies of the differential effect on syncytial and cytotrophoblast had not been carried out. She thought that from the technical point of view such a study might present some problems. But equally, it was important to determine the specific part of the cell in which the different reactions occurred. In fact, in some ways this might be technically easier than study of the separate tissues.
In reply to another speaker, Dr Ginsburg said that although she and her colleagues had not specifically investigated the effect of monoamine-oxidase inhibitors on the pattern of placental glucose metabolism, they had incubated placental tissue with adrenaline in the presence and absence of monoamine-oxidase inhibitors and the response to adrenaline had not been affected. Hence the effect of adrenaline in different conditions was not apparently related to the activity of placental monoamine-oxidase.
Fetal Diagnosis by R W Beard' MB MRCOG (Institute ofObstetrics & Gynecology, London)
I should like to adopt a practical approach to the subject of foetal diagnosis and consider how diagnostic methods can be used to reduce still further the low perinatal mortality that exists in most hospitals in this country. To define this problem, I have analysed the stillbirths and neonatal deaths which have occurred at Queen Charlotte's Hospital over a five-year period between 1963 and 1967. The mean perinatal mortality during this five-year period was 27-9 per 1,000 births; 59 % of these babies were stillbirths dying prior to the onset of labour or during labour. Intrauterine asphyxia was the major cause of these stillbirths, and accounted for 65 % of these deaths, or 400% of the overall perinatal mortality. Most of the babies dying from this cause were at a stage of development that would enable them to survive extrauterine life if they could have been delivered before death. This is in contrast to the high incidence of prematurity contributing to neonatal mortality. It is clear from these figures that any diagnostic test that can reliably detect at an early stage some evidence that placental function is failing, or that foetal homeostasis is disturbed, would lead to a substantial reduction in perinatal mortality. Not surprisingly, no single test of sufficient versatility, 'Present Address: King's College Hospital, London
